1. El‐SeragHB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology2012;142:1264. CrossRef

2. MeissnerHI, SmithRA, RimerBK, et al.Promoting cancer screening: learning from experience. Cancer2004;101:1107. CrossRef

3. ArguedasMR, ChenVK, EloubeidiMA, et al.Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost‐utility analysis. Am J Gastroenterol2003;98:679. CrossRef

4. BruixJ, ShermanM. Management of hepatocellular carcinoma: an update. Hepatology2010;53:1. CrossRef

5. LinOS, KeeffeEB, SandersGD, et al.Cost‐effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther2004;19:1159. CrossRef

6. SarasinFP, GiostraE, HadengueA. Cost‐effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child‐Pugh class A cirrhosis. Am J Med1996;101:422. CrossRef

7. CollierJ, ShermanM. Screening for hepatocellular carcinoma. Hepatology1998;27:273. CrossRef

8. BeasleyR. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer1988;61:1942. CrossRef

9. BeasleyR. Hepatitis B virus as the etiologic agent in hepatocellular carcinoma‐ epidemiologic considerations. Hepatology1982;2:21S.

10. BeasleyR, HwangLY, LinCC, et al.Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet1981;2:1129. CrossRef

11. de FranchisR, MeucciG, VecchiM, et al.The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med1993;118:191. CrossRef

12. EvansAA, ChenG, RossEA, et al.Eight‐year follow‐up of the 90,000‐person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev2002;11:369.

13. HsuYS, ChienRN, YehCT, et al.Long‐term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology2002;35:1522. CrossRef

14. Sanchez‐TapiasJM, CostaJ, MasA, et al.Influence of hepatitis B virus genotype on the long‐term outcome of chronic hepatitis B in western patients. Gastroenterology2002;123:1848. CrossRef

15. YangHI, LuSN, LiawYF, et al.Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med2002;347:168. CrossRef

16. HuoTI, WuJC, LeePC, et al.Sero‐clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology1998;28:231. CrossRef

17. FattovichG, StroffoliniT, ZagniI, et al.Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology2004;127:S35. CrossRef

18. VilleneuveJP, DesrochersM, Infante‐RivardC, et al.A long‐term follow‐up study of asymptomatic hepatitis B surface antigen‐positive carriers in Montreal. Gastroenterology1994;106:1000.

19. McMahonBJ, AlbertsSR, WainwrightRB, et al.Hepatitis B‐related sequelae. Prospective study in 1400 hepatitis B surface antigen‐positive Alaska native carriers. Arch Intern Med1990;150:1051. CrossRef

20. ShermanM, PeltekianKM, LeeC. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology1995;22:432.

21. YuMW, ChangHC, LiawYF, et al.Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst2000;92:1159. CrossRef

22. KewMC, MacerolloP. Effect of age on the etiologic role of the hepatitis B virus in hepatocellular carcinoma in blacks. Gastroenterology1988;94:439.

23. YangJD, KimWR, CoelhoR, et al.Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol2011;9:64. CrossRef

24. El‐SeragHB, RudolphKL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology2007;132:2557. CrossRef

25. YangHI, ShermanM, SuJ, et al.Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol2010;28:2437. CrossRef

26. YuenMF, TanakaY, FongDY, et al.Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol2009;50:80. CrossRef

27. ChanHL, TseCH, MoF, et al.High viral load and hepatitis B virus subgenotype are associated with increased risk of hepatocellular carcinoma. J Clin Oncol2008;26:177. CrossRef

28. ChenCJ, YangHI, SuJ, et al.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA2006;295:65. CrossRef

29. ChenJD, YangHI, IloejeUH, et al.Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver‐related death. Gastroenterology2010;138:1747. CrossRef

30. El‐SeragHB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology2004;127:S27. CrossRef

31. DonatoF, BoffettaP, PuotiM. A meta‐analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer1998;75:347. CrossRef

32. FattovichG, GiustinaG, DegosF, et al.Morbidity and mortality in compensated cirrhosis type C: a retrospective follow‐up study of 384 patients. Gastroenterology1997;112:463. CrossRef

33. NiederauC, LangeS, HeintgesT, et al.Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology1998;28:1687. CrossRef

34. SunCA, WuDM, LinCC, et al.Incidence and cofactors of hepatitis C virus‐related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol2003;157:674. CrossRef

35. YoshidaH, ShiratoriY, MoriyamaM, et al.Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med1999;131:174. CrossRef

36. LokAS, SeeffLB, MorganTR, et al.Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C‐related advanced liver disease. Gastroenterology2009;136:138. CrossRef

37. FreemanAJ, DoreGJ, LawMG, et al.Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology2001;34:809. CrossRef

38. PoynardT, BedossaP, OpolonP. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet1997;349:825. CrossRef

39. ThomasDL, AstemborskiJ, RaiRM, et al.The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA2000;284:450. CrossRef

40. BraksRE, Ganne‐CarrieN, FontaineH, et al.Effect of sustained virological response on long‐term clinical outcome in 113 patients with compensated hepatitis C‐related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol2007;13:5648. CrossRef

41. BrunoS, StroffoliniT, ColomboM, et al.Sustained virological response to interferon‐alpha is associated with improved outcome in HCV‐related cirrhosis: a retrospective study. Hepatology2007;45:579. CrossRef

42. VeldtBJ, HeathcoteEJ, WedemeyerH, et al.Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med2007;147:677. CrossRef

43. SingalAG, VolkML, JensenD, et al.A sustained viral response is associated with reduced liver‐related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol2010;8:280, 288 e281. CrossRef

44. SingalAG, WaljeeA, MukherjeeA, et al.Machine learning algorithms outperform conventional regression models in identifying risk factors for hepatocellular carcinoma in patients with cirrhosis. Gastroenterology2012;142:S984. CrossRef

45. WelzelTM, GraubardBI, ZeuzemS, et al.Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER‐Medicare database. Hepatology2011;54:463. CrossRef

46. TuratiF, TalaminiR, PelucchiC, et al.Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer2013;108:222. CrossRef

47. BugianesiE. Non‐alcoholic steatohepatitis and cancer. Clin Liver Dis2007;11:191, x. CrossRef

48. CalleEE, RodriguezC, Walker‐ThurmondK, et al.Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med2003;348:1625. CrossRef

49. MollerH, MellemgaardA, LindvigK, et al.Obesity and cancer risk: a Danish record‐linkage study. Eur J Cancer1994;30A:344. CrossRef

50. WolkA, GridleyG, SvenssonM, et al.A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control2001;12:13. CrossRef

51. El‐SeragHB, RichardsonPA, EverhartJE. The role of diabetes in hepatocellular carcinoma: a case‐control study among United States Veterans. Am J Gastroenterol2001;96:2462. CrossRef

52. AdamiHO, ChowWH, NyrenO, et al.Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst1996;88:1472. CrossRef

53. LagiouP, KuperH, StuverSO, et al.Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst2000;92:1096. CrossRef

54. WideroffL, GridleyG, MellemkjaerL, et al.Cancer incidence in a population‐based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst1997;89:1360. CrossRef

55. El‐SeragHB, TranT, EverhartJE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology2004;126:460. CrossRef

56. WangP, KangD, CaoW, et al.Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta‐analysis. Diabetes Metab Res Rev2012;28:109. CrossRef

57. El‐SeragHB, JohnsonML, HachemC, et al.Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology2009;136:1601. CrossRef

58. Dam‐LarsenS, BeckerU, FranzmannMB, et al.Final results of a long‐term, clinical follow‐up in fatty liver patients. Scand J Gastroenterol2009;44:1236. CrossRef

59. SoderbergC, StalP, AsklingJ, et al.Decreased survival of subjects with elevated liver function tests during a 28‐year follow‐up. Hepatology2010;51:595. CrossRef

60. WhiteDL, KanwalF, El‐SeragHB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol2012;10:1342. CrossRef

61. AschaMS, HanounehIA, LopezR, et al.The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology2010;51:1972. CrossRef

62. SorensenHT, FriisS, OlsenJH, et al.Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology1998;28:921. CrossRef

63. StarleyBQ, CalcagnoCJ, HarrisonSA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology2010;51:1820. CrossRef

64. AdamiHO, HsingAW, McLaughlinJK, et al.Alcoholism and liver cirrhosis in the etiology of primary liver cancer. Int J Cancer1992;51:898. CrossRef

65. BagnardiV, BlangiardoM, La VecchiaC, et al.A meta‐analysis of alcohol drinking and cancer risk. Br J Cancer2001;85:1700. CrossRef

66. HassanMM, HwangLY, HattenCJ, et al.Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology2002;36:1206. CrossRef

67. JepsenP, OttP, AndersenPK, et al.Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a danish nationwide cohort study. Ann Intern Med2012;156:841. CrossRef

68. La VecchiaC. Alcohol and liver cancer. Eur J Cancer Prev2007;16:495. CrossRef

69. MorganTR, MandayamS, JamalMM. Alcohol and hepatocellular carcinoma. Gastroenterology2004;127:S87. CrossRef

70. DonatoF, TaggerA, GelattiU, et al.Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol2002;155:323. CrossRef

71. MarreroJA, FontanaRJ, FuS, et al.Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol2005;42:218. CrossRef

72. ElmbergM, HultcrantzR, EkbomA, et al.Cancer risk in patients with hereditary hemochromatosis and in their first‐degree relatives. Gastroenterology2003;125:1733. CrossRef

73. JonesDE, MetcalfJV, CollierJD, et al.Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology1997;26:1138. CrossRef

74. PropstT, PropstA, DietzeO, et al.Prevalence of hepatocellular carcinoma in alpha‐1‐antitrypsin deficiency. J Hepatol1994;21:1006. CrossRef

75. FracanzaniAL, ConteD, FraquelliM, et al.Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non‐iron‐related chronic liver disease. Hepatology2001;33:647. CrossRef

76. HsingAW, McLaughlinJK, OlsenJH, et al.Cancer risk following primary hemochromatosis: a population‐based cohort study in Denmark. Int J Cancer1995;60:160. CrossRef

77. CaballeriaL, ParesA, CastellsA, et al.Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus‐related cirrhosis. Am J Gastroenterol2001;96:1160.

78. BressacB, KewM, WandsJ, et al.Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature1991;350:429. CrossRef

79. QianGS, RossRK, YuMC, et al.A follow‐up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev1994;3:3.

80. ChomaratP, RiceJM, SlagleBL, et al.Hepatitis B virus‐induced liver injury and altered expression of carcinogen metabolising enzymes: the role of the HBx protein. Toxicol Lett1998;102–103:595. CrossRef

81. TurnerPC, SyllaA, DialloMS, et al.The role of aflatoxins and hepatitis viruses in the etiopathogenesis of hepatocellular carcinoma: a basis for primary prevention in Guinea‐Conakry, West Africa. J Gastroenterol Hepatol2002;17(Suppl):S441. CrossRef

82. AnthonyJC, Echeagaray‐WagnerF. Epidemiologic analysis of alcohol and tobacco use. Alcohol Res Health2000;24:201.

83. YuMW, ChangHC, ChangSC, et al.Role of reproductive factors in hepatocellular carcinoma: impact on hepatitis B‐ and C‐related risk. Hepatology2003;38:1393.

84. El‐SeragHB, LauM, EschbachK, et al.Epidemiology of hepatocellular carcinoma in Hispanics in the United States. Arch Intern Med2007;167:1983. CrossRef

85. KuperH, TzonouA, KaklamaniE, et al.Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer2000;85:498. CrossRef

86. JeeSH, OhrrH, SullJW, et al.Cigarette smoking, alcohol drinking, hepatitis B, and risk for hepatocellular carcinoma in Korea. J Natl Cancer Inst2004;96:1851. CrossRef

87. FranceschiS, MontellaM, PoleselJ, et al.Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. Cancer Epidemiol Biomarkers Prev2006;15:683. CrossRef

88. MoriM, HaraM, WadaI, et al.Prospective study of hepatitis B and C viral infections, cigarette smoking, alcohol consumption, and other factors associated with hepatocellular carcinoma risk in Japan. Am J Epidemiol2000;151:131. CrossRef

89. YuMW, HorngIS, HsuKH, et al.Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis virus infection. Am J Epidemiol1999;150:367. CrossRef

90. YuMW, HsiehHH, PanWH, et al.Vegetable consumption, serum retinol level, and risk of hepatocellular carcinoma. Cancer Res1995;55:1301.

91. SauvagetC, NaganoJ, HayashiM, et al.Vegetables and fruit intake and cancer mortality in the Hiroshima/Nagasaki Life Span Study. Br J Cancer2003;88:689. CrossRef

92. KuperH, TzonouA, LagiouP, et al.Diet and hepatocellular carcinoma: a case‐control study in Greece. Nutr Cancer2000;38:6. CrossRef

93. UmemuraT, IchijoT, YoshizawaK, et al.Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol2009;44:102. CrossRef

94. TanakaY, HanadaK, MizokamiM, et al.A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A2002;99:15584. CrossRef

95. AltekruseSF, McGlynnKA, DickieLA, et al.Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992‐2008. Hepatology2012;55:476. CrossRef

96. AltekruseSF, McGlynnKA, ReichmanME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol2009;27:1485. CrossRef

97. El‐SeragHB, DavilaJA, PetersenNJ, et al.The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med2003;139:817. CrossRef

98. SheblFM, Capo‐RamosDE, GraubardBI, et al.Socioeconomic status and hepatocellular carcinoma in the United States. Cancer Epidemiol Biomarkers Prev2012;21:1330. CrossRef

99. ThorgeirssonSS, GrishamJW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet2002;31:339. CrossRef

100. HanahanD, WeinbergRA. The hallmarks of cancer. Cell2000;100:57. CrossRef

101. GreenDR, EvanGI. A matter of life and death. Cancer Cell2002;1:19. CrossRef

102. SchmittCA, FridmanJS, YangM, et al.Dissecting p53 tumor suppressor functions in vivo. Cancer Cell2002;1:289. CrossRef

103. PikarskyE, PoratRM, SteinI, et al.NF‐kappaB functions as a tumour promoter in inflammation‐associated cancer. Nature2004;431:461. CrossRef

104. RobertsLR, GoresGJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis2005;25:212. CrossRef

105. StrumbergD, RichlyH, HilgerRA, et al.Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43‐9006 in patients with advanced refractory solid tumors. J Clin Oncol2005;23:965. CrossRef

106. YouL, HeB, XuZ, et al.An anti‐Wnt‐2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res2004;64:5385. CrossRef

107. GilesRH, van EsJH, CleversH. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta2003;1653:1.

108. WillertK, BrownJD, DanenbergE, et al.Wnt proteins are lipid‐modified and can act as stem cell growth factors. Nature2003;423:448. CrossRef

109. LepourceletM, ChenYN, FranceDS, et al.Small‐molecule antagonists of the oncogenic Tcf/beta‐catenin protein complex. Cancer Cell2004;5:91. CrossRef

110. EmamiKH, NguyenC, MaH, et al.A small molecule inhibitor of beta‐catenin/CREB‐binding protein transcription [corrected]. Proc Natl Acad Sci U S A2004;101:12682. CrossRef

111. YouL, HeB, XuZ, et al.Inhibition of Wnt‐2‐mediated signaling induces programmed cell death in non‐small‐cell lung cancer cells. Oncogene2004;23:6170. CrossRef

112. SinghR, CzajaMJ. Capitalizing on AKT signaling to inhibit hepatocellular carcinoma cell proliferation. Cancer Biol Ther2005;4:1419. CrossRef

113. TanakaS, AriiS. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci2009;100:1. CrossRef

114. ChanS. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer2004;91:1420. CrossRef

115. MaxwellPH, DachsGU, GleadleJM, et al.Hypoxia‐inducible factor‐1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A1997;94:8104. CrossRef

116. MussoO, RehnM, TheretN, et al.Tumor progression is associated with a significant decrease in the expression of the endostatin precursor collagen XVIII in human hepatocellular carcinomas. Cancer Res2001;61:45.

117. MiuraN, HorikawaI, NishimotoA, et al.Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis. Cancer Genet Cytogenet1997;93:56. CrossRef

118. StewartSA, WeinbergRA. Telomerase and human tumorigenesis. Semin Cancer Biol2000;10:399. CrossRef

119. KojimaH, YokosukaO, ImazekiF, et al.Telomerase activity and telomere length in hepatocellular carcinoma and chronic liver disease. Gastroenterology1997;112:493. CrossRef

120. NagaoK, TomimatsuM, EndoH, et al.Telomerase reverse transcriptase mRNA expression and telomerase activity in hepatocellular carcinoma. J Gastroenterol1999;34:83. CrossRef

121. PardalR, ClarkeMF, MorrisonSJ. Applying the principles of stem‐cell biology to cancer. Nat Rev Cancer2003;3:895. CrossRef

122. DimriGP, MartinezJL, JacobsJJ, et al.The Bmi‐1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res2002;62:4736.

123. EffendiK, MoriT, KomutaM, et al.Bmi‐1 gene is upregulated in early‐stage hepatocellular carcinoma and correlates with ATP‐binding cassette transporter B1 expression. Cancer Sci2010;101:666. CrossRef

124. TrevisaniF, D'IntinoPE, CaraceniP, et al.Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patients. Cancer1995;75:2220. CrossRef

125. TrevisaniF, DeNS, RapacciniG, et al.Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol2002;97:734. CrossRef

126. YuenMF, ChengCC, LauderIJ, et al.Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology2000;31:330. CrossRef

127. SingalAG, YoppAC, GuptaS, et al.Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila)2012;5:1124. CrossRef

128. NatsuizakaM, OmuraT, AkaikeT, et al.Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol2005;20:1781. CrossRef

129. LuoJC, HwangSJ, WuJC, et al.Clinical characteristics and prognosis of hepatocellular carcinoma patients with paraneoplastic syndromes. Hepatogastroenterology2002;49:1315.

130. ChalasaniN, SaidA, NessR, et al.Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey. Am J Gastroenterol1999;94:2224. CrossRef

131. LarcosG, SorokopudH, BerryG, et al.Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation. Am J Roentgenol1998;171:433. CrossRef

132. SingalA, MarreroJ. Screening for hepatocellular carcinoma. Gastroenterol Hepatol2008;4:1.

133. ZhangB, YangB. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J Med Screen1999;6:108. CrossRef

134. SingalA, VolkML, WaljeeA, et al.Meta‐analysis: surveillance with ultrasound for early‐stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther2009;30:37. CrossRef

135. LokAS, SterlingRK, EverhartJE, et al.Des‐gamma‐carboxy prothrombin and alpha‐fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology2010;138:493. CrossRef

136. SingalAG, ConjeevaramHS, VolkML, et al.Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev2012;21:793. CrossRef

137. FinbergHJ. Whither (wither?) the ultrasound specialist?J Ultrasound Med2004;23:1543.

138. OlsenAH, BihrmannK, JensenMB, et al.Breast density and outcome of mammography screening: a cohort study. Br J Cancer2009;100:1205. CrossRef

139. MarreroJA. Screening tests for hepatocellular carcinoma. Clin Liver Dis2005;9:235, vi. CrossRef

140. ColliA, FraquelliM, CasazzaG, et al.Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha‐fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol2006;101:513. CrossRef

141. TrevisaniF, D'IntinoPE, Morselli‐LabateAM, et al.Serum alpha‐fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti‐HCV status. J Hepatol2001;34:570. CrossRef

142. GuptaS, BentS, KohlwesJ. Test characteristics of alpha‐fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med2003;139:46. CrossRef

143. MarreroJA, FengZ, WangY, et al.Alpha‐fetoprotein, des‐gamma carboxyprothrombin, and lectin‐bound alpha‐fetoprotein in early hepatocellular carcinoma AFP, DCP, and AFP‐L3 in hepatocellular carcinoma. Gastroenterology2009;137:110. CrossRef

144. LeeE, EdwardS, SingalAG, et al.Improving screening for hepatocellular carcinoma by incorporating data on levels of alpha‐fetoprotein, over time. Clin Gastroenterol Hepatol2013;11:437. CrossRef

145. MarreroJA, El‐SeragHB. Alpha‐fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the American Association for the Study of Liver Diseases. Hepatology2011;53:1060; author reply 1061. CrossRef

146. SatoY, NakataK, KatoY, et al.Early recognition of hepatocellular carcinoma based on altered profiles of alpha‐fetoprotein. N Engl J Med1993;328:1802. CrossRef

147. OnoM, OhtaH, OhhiraM, et al.Measurement of immunoreactive prothrombin precursor and vitamin‐K‐dependent gamma‐carboxylation in human hepatocellular carcinoma tissues: decreased carboxylation of prothrombin precursor as a cause of des‐gamma‐carboxyprothrombin synthesis. Tumour Biol1990;11:319. CrossRef

148. IkomaJ, KaitoM, IshiharaT, et al.Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des‐gamma‐carboxy prothrombin: a prospective study. Hepatogastroenterology2002;49:235.

149. IshiiM, GamaH, ChidaN, et al.Simultaneous measurements of serum alpha‐fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol2000;95:1036.

150. IzunoK, FujiyamaS, YamasakiK, et al.Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des‐gamma‐carboxy prothrombin and alpha‐fetoprotein: a prospective study. Hepatogastroenterology1995;42:387.

151. ShirakiK, TakaseK, TamedaY, et al.A clinical study of lectin‐reactive alpha‐fetoprotein as an early indicator of hepatocellular carcinoma in the follow‐up of cirrhotic patients. Hepatology1995;22:802. CrossRef

152. SterlingRK, JeffersL, GordonF, et al.Clinical utility of AFP‐L3% measurement in North American patients with HCV‐related cirrhosis. Am J Gastroenterol2007;102:2196. CrossRef

153. SterlingRK, JeffersL, GordonF, et al.Utility of Lens culinaris agglutinin‐reactive fraction of alpha‐fetoprotein and des‐gamma‐carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol2009;7:104. CrossRef

154. TaketaK, SekiyaC, NamikiM, et al.Lectin‐reactive profiles of alpha‐fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology1990;99:508.

155. CapurroM, WanlessIR, ShermanM, et al.Glypican‐3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology2003;125:89. CrossRef

156. LlovetJM, ChenY, WurmbachE, et al.A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology2006;131:1758. CrossRef

157. MarreroJA, RomanoPR, NikolaevaO, et al.GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol2005;43:1007. CrossRef

158. ShangS, PlymothA, GeS, et al.Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology2012;55:483. CrossRef

159. BeneduceL, CastaldiF, MarinoM, et al.Squamous cell carcinoma antigen‐immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma. Cancer2005;103:2558. CrossRef

160. YamagamiH, MoriyamaM, TanakaN, et al.Detection of serum and intrahepatic human hepatocyte growth factor in patients with type C liver diseases. Intervirology2001;44:36. CrossRef

161. MazziottiG, SorvilloF, MoriscoF, et al.Serum insulin‐like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis: a prospective study. Cancer2002;95:2539. CrossRef

162. ChignardN, BerettaL. Proteomics for hepatocellular carcinoma marker discovery. Gastroenterology2004;127:S120. CrossRef

163. PepeMS, EtzioniR, FengZ, et al.Phases of biomarker development for early detection of cancer. J Natl Cancer Inst2001;93:1054. CrossRef

164. TrinchetJC, ChaffautC, BourcierV, et al.Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3‐ and 6‐month periodicities. Hepatology2011;54:1987. CrossRef

165. YangB, ZhangB, XuY, et al.Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol1997;123:357. CrossRef

166. ZhangBH, YangBH, TangZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol2004;130:417.

167. El‐SeragHB, KramerJR, ChenGJ, et al.Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV‐infected patients in the USA. Gut2011;60:992. CrossRef

168. LaupacisA, FeenyD, DetskyAS, et al.How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ1992;146:473.

169. KobayashiM, IkedaK, HosakaT, et al.Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer2006;106:636. CrossRef

170. BorzioM, BorzioF, CroceA, et al.Ultrasonography‐detected macroregenerative nodules in cirrhosis: a prospective study. Gastroenterology1997;112:1617. CrossRef

171. BorzioM, FargionS, BorzioF, et al.Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol2003;39:208. CrossRef

172. LlovetJM, BustamanteJ, CastellsA, et al.Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology1999;29:62. CrossRef

173. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology1998;28:751.

174. BarbaraL, BenziG, GaianiS, et al.Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology1992;16:132. CrossRef

175. EsnaolaNF, LauwersGY, MirzaNQ, et al.Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg2002;6:224; discussion 232. CrossRef

176. KanematsuM, SemelkaRC, LeonardouP, et al.Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations. J Magn Reson Imaging2003;18:189. CrossRef

177. TrevisaniF, CaraceniP, BernardiM, et al.Gross pathologic types of hepatocellular carcinoma in Italian patients. Relationship with demographic, environmental, and clinical factors. Cancer1993;72:1557. CrossRef

178. KneuertzPJ, DemirjianA, FiroozmandA, et al.Diffuse infiltrative hepatocellular carcinoma: assessment of presentation, treatment, and outcomes. Ann Surg Oncol2012;19:2897. CrossRef

179. CottoneM, VirdoneR, FuscoG, et al.Asymptomatic hepatocellular carcinoma in Child's A cirrhosis. A comparison of natural history and surgical treatment. Gastroenterology1989;96:1566.

180. EbaraM, OhtoM, ShinagawaT, et al.Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients. Gastroenterology1986;90:289.

181. KubotaK, InaH, OkadaY, et al.Growth rate of primary single hepatocellular carcinoma: determining optimal screening interval with contrast enhanced computed tomography. Dig Dis Sci2003;48:581. CrossRef

182. OkazakiN, YoshinoM, YoshidaT, et al.Evaluation of the prognosis for small hepatocellular carcinoma based on tumor volume doubling time. A preliminary report. Cancer1989;63:2207. CrossRef

183. CapocacciaR, SantM, BerrinoF, et al.Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol2007;102:1661; quiz 1660, 1671. CrossRef

184. DavilaJA, HendersonL, KramerJR, et al.Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus‐infected veterans in the United States. Ann Intern Med2011;154:85. CrossRef

185. DavilaJA, MorganRO, RichardsonPA, et al.Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology2010;52:132. CrossRef

186. SingalAG, NehraM, Adams‐HuetB, et al.Detection of hepatocellular carcinoma at advanced stages among patients in the HALT‐C trial: where did surveillance fail?Am J Gastroenterol2013;108:425. CrossRef

187. SingalAG, TiroJA, GuptaS. Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening. Clin Gastroenterol Hepatol2013;11:472. CrossRef

188. SingalAG, YoppA, SkinnerC, et al.Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med2012;27:861. CrossRef

189. FlemingID. AJCC/TNM cancer staging, present and future. J Surg Oncol2001;77:233. CrossRef

190. MarreroJA, FontanaRJ, BarratA, et al.Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology2005;41:707. CrossRef

191. CilloU, VitaleA, GrigolettoF, et al.Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol2006;44:723. CrossRef

192. BruixJ, ShermanM. Management of hepatocellular carcinoma: an update. Hepatology2011;53:1020. CrossRef

193. ChenCH, HuFC, HuangGT, et al.Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method–analysis of 2010 Taiwanese patients. Eur J Cancer2009;45:1630. CrossRef

194. IwasakiM, FuruseJ, YoshinoM, et al.Sonographic appearances of small hepatic nodules without tumor stain on contrast‐enhanced computed tomography and angiography. J Clin Ultrasound1998;26:303. CrossRef

195. JeongYY, MitchellDG, KamishimaT. Small (<20 mm) enhancing hepatic nodules seen on arterial phase MR imaging of the cirrhotic liver: clinical implications. Am J Roentgenol2002;178:1327 CrossRef

196. FornerA, VilanaR, AyusoC, et al.Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology2008;47:97. CrossRef

197. MarreroJA, HussainHK, NghiemHV, et al.Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially‐enhancing liver mass. Liver Transpl2005;11:281. CrossRef

198. MuellerGC, HussainHK, CarlosRC, et al.Effectiveness of MR imaging in characterizing small hepatic lesions: routine versus expert interpretation. Am J Roentgenol2003;180:673. CrossRef

199. ShimizuA, ItoK, KoikeS, et al.Cirrhosis or chronic hepatitis: evaluation of small (< or =2 cm) early‐enhancing hepatic lesions with serial contrast‐enhanced dynamic MR imaging. Radiology2003;226:550. CrossRef

200. TaouliB, GohJS, LuY, et al.Growth rate of hepatocellular carcinoma: evaluation with serial computed tomography or magnetic resonance imaging. J Comput Assist Tomogr2005;29:425. CrossRef

201. LeoniS, PiscagliaF, GolfieriR, et al.The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol2010;105:599. CrossRef

202. SangiovanniA, ManiniMA, IavaroneM, et al.The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut2010;59:638. CrossRef

203. SersteT, BarrauV, OzenneV, et al.Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology2012;55:800. CrossRef

204. BurrelM, LlovetJM, AyusoC, et al.MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology2003;38:1034. CrossRef

205. KangBK, LimJH, KimSH, et al.Preoperative depiction of hepatocellular carcinoma: ferumoxides‐enhanced MR imaging versus triple‐phase helical CT. Radiology2003;226:79. CrossRef

206. KrinskyGA, LeeVS. MR imaging of cirrhotic nodules. Abdom Imaging2000;25:471. CrossRef

207. RodeA, BancelB, DouekP, et al.Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr2001;25:327. CrossRef

208. StokerJ, RomijnMG, de ManRA, et al.Prospective comparative study of spiral computer tomography and magnetic resonance imaging for detection of hepatocellular carcinoma. Gut2002;51:105. CrossRef

209. GaianiS, CelliN, PiscagliaF, et al.Usefulness of contrast‐enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. J Hepatol2004;41:421. CrossRef

210. QuaiaE, CalliadaF, BertolottoM, et al.Characterization of focal liver lesions with contrast‐specific US modes and a sulfur hexafluoride‐filled microbubble contrast agent: diagnostic performance and confidence. Radiology2004;232:420. CrossRef

211. TeefeySA, HildeboldtCC, DehdashtiF, et al.Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology2003;226:533. CrossRef

212. KelekisNL, SemelkaRC, WorawattanakulS, et al.Hepatocellular carcinoma in North America: a multiinstitutional study of appearance on T1‐weighted, T2‐weighted, and serial gadolinium‐enhanced gradient‐echo images. Am J Roentgenol1998;170:1005. CrossRef

213. WillattJM, HussainHK, AdusumilliS, et al.MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology2008;247:311. CrossRef

214. ShinmuraR, MatsuiO, KobayashiS, et al.Cirrhotic nodules: association between MR imaging signal intensity and intranodular blood supply. Radiology2005;237:512. CrossRef

215. EfremidisSC, HytiroglouP. The multistep process of hepatocarcinogenesis in cirrhosis with imaging correlation. Eur Radiol2002;12:753. CrossRef

216. MatsuiO. Imaging of multistep human hepatocarcinogenesis by CT during intra‐arterial contrast injection. Intervirology2004;47:271. CrossRef

217. HyodoT, MurakamiT, ImaiY, et al.Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma. Radiology2013;266:480. CrossRef

218. TakayasuK, AriiS, SakamotoM, et al.Clinical implication of hypovascular hepatocellular carcinoma studied in 4,474 patients with solitary tumour equal or less than 3 cm. Liver Int2013;33:762. CrossRef

219. MadanK, KudoM, FukutaN. Multistep progression from a hypovascular nodule to a nodule‐in‐nodule type hepatocellular carcinoma in hepatitis C‐related cirrhosis. Indian J Gastroenterol2008;27:176.

220. BuscariniL, FornariF, BolondiL, et al.Ultrasound‐guided fine‐needle biopsy of focal liver lesions: techniques, diagnostic accuracy and complications. A retrospective study on 2091 biopsies. J Hepatol1990;11:344. CrossRef

221. HertzG, ReddyVB, GreenL, et al.Fine‐needle aspiration biopsy of the liver: a multicenter study of 602 radiologically guided FNA. Diagn Cytopathol2000;23:326. CrossRef

222. WangP, MengZQ, ChenZ, et al.Diagnostic value and complications of fine needle aspiration for primary liver cancer and its influence on the treatment outcome‐a study based on 3011 patients in China. Eur J Surg Oncol2008;34:541. CrossRef

223. SilvaMA, HegabB, HydeC, et al.Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta‐analysis. Gut2008;57:1592. CrossRef

224. MaturenKE, NghiemHV, MarreroJA, et al.Lack of tumor seeding of hepatocellular carcinoma after percutaneous needle biopsy using coaxial cutting needle technique. Am J Roentgenol2006;187:1184. CrossRef

225. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology2009;49:658. CrossRef

226. ParkYN, YangCP, FernandezGJ, et al.Neoangiogenesis and sinusoidal "capillarization" in dysplastic nodules of the liver. Am J Surg Pathol1998;22:656. CrossRef

227. WatanabeS, OkitaK, HaradaT, et al.Morphologic studies of the liver cell dysplasia. Cancer1983;51:2197. CrossRef

228. ParkYN, KojiroM, Di TommasoL, et al.Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules. Cancer2007;109:915. CrossRef

229. HytiroglouP. Morphological changes of early human hepatocarcinogenesis. Semin Liver Dis2004;24:65. CrossRef

230. HytiroglouP, ParkYN, KrinskyG, et al.Hepatic precancerous lesions and small hepatocellular carcinoma. Gastroenterol Clin North Am2007;36:867, vii. CrossRef

231. Di TommasoL, DestroA, SeokJY, et al.The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol2009;50:746. CrossRef

232. Di TommasoL, FranchiG, ParkYN, et al.Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology2007;45:725. CrossRef

233. GarridoC, GurbuxaniS, RavagnanL, et al.Heat shock proteins: endogenous modulators of apoptotic cell death. Biochem Biophys Res Commun2001;286:433. CrossRef

234. LibbrechtL, SeveriT, CassimanD, et al.Glypican‐3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia‐like nodules. Am J Surg Pathol2006;30:1405. CrossRef

235. MidorikawaY, IshikawaS, IwanariH, et al.Glypican‐3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP‐7 signaling. Int J Cancer2003;103:455. CrossRef

236. WangXY, DegosF, DuboisS, et al.Glypican‐3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol2006;37:1435. CrossRef

237. YamauchiN, WatanabeA, HishinumaM, et al.The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol2005;18:1591.

238. ZhuZW, FriessH, WangL, et al.Enhanced glypican‐3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut2001;48:558. CrossRef

239. LimSO, ParkSG, YooJH, et al.Expression of heat shock proteins (HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus‐related hepatocellular carcinomas and dysplastic nodules. World J Gastroenterol2005;11:2072. CrossRef

240. SakamotoM, MoriT, MasugiY, et al.Candidate molecular markers for histological diagnosis of early hepatocellular carcinoma. Intervirology2008;51:42. CrossRef

241. TremosiniS, FornerA, BoixL, et al.Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. Gut2012;61:1481. CrossRef

242. TrevisaniF, FrigerioM, SantiV, et al.Hepatocellular carcinoma in non‐cirrhotic liver: a reappraisal. Dig Liver Dis2010;42:341. CrossRef

243. BismuthH, MajnoPE. Hepatobiliary surgery. J Hepatol2000;32:208. CrossRef

244. PoonRT, FanST, LoCM, et al.Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg2004;240:698; discussion 708.

245. SimonsJP, NgSC, HillJS, et al.In‐hospital mortality from liver resection for hepatocellular carcinoma: a simple risk score. Cancer2010;116:1733. CrossRef

246. FargesO, MalassagneB, FlejouJF, et al.Risk of major liver resection in patients with underlying chronic liver disease: a reappraisal. Ann Surg1999;229:210. CrossRef

247. de GraafW, van LiendenKP, van den EsschertJW, et al.Increase in future remnant liver function after preoperative portal vein embolization. Br J Surg2011;98:825. CrossRef

248. FargesO, BelghitiJ, KianmaneshR, et al.Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg2003;237:208.

249. CucchettiA, ErcolaniG, VivarelliM, et al.Impact of model for end‐stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl2006;12:966. CrossRef

250. DelisSG, BakoyiannisA, DervenisC, et al.Perioperative risk assessment for hepatocellular carcinoma by using the MELD score. J Gastrointest Surg2009;13:2268. CrossRef

251. TehSH, ChristeinJ, DonohueJ, et al.Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End‐Stage Liver Disease (MELD) score predicts perioperative mortality. J Gastrointest Surg2005;9:1207; discussion 1215. CrossRef

252. LlovetJM, FusterJ, BruixJ. Intention‐to‐treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology1999;30:1434. CrossRef

253. BruixJ, CastellsA, BoschJ, et al.Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology1996;111:1018. CrossRef

254. IshizawaT, HasegawaK, KokudoN, et al.Risk factors and management of ascites after liver resection to treat hepatocellular carcinoma. Arch Surg2009;144:46. CrossRef

255. StremitzerS, TamandlD, KaczirekK, et al.Value of hepatic venous pressure gradient measurement before liver resection for hepatocellular carcinoma. Br J Surg2011;98:1752. CrossRef

256. TaketomiA, KitagawaD, ItohS, et al.Trends in morbidity and mortality after hepatic resection for hepatocellular carcinoma: an institute's experience with 625 patients. J Am Coll Surg2007;204:580. CrossRef

257. IkaiI, AriiS, KojiroM, et al.Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer2004;101:796. CrossRef

258. AriiS, YamaokaY, FutagawaS, et al.Results of surgical and nonsurgical treatment for small‐sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology2000;32:1224. CrossRef

259. ZhouXD, TangZY, YangBH, et al.Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer2001;91:1479. CrossRef

260. KianmaneshR, RegimbeauJM, BelghitiJ. Selective approach to major hepatic resection for hepatocellular carcinoma in chronic liver disease. Surg Oncol Clin N Am2003;12:51. CrossRef

261. ChungCD, LauLL, KoKL, et al.Laparoscopic liver resection for hepatocellular carcinoma. Asian J Surg2010;33:168. CrossRef

262. NguyenKT, GamblinTC, GellerDA. World review of laparoscopic liver resection – 2,804 patients. Ann Surg2009;250:831. CrossRef

263. YoppA, SingalA. Laparoscopic liver resection for hepatocellular carcinoma: indications and role. Clin Liver Dis2012;1:206. CrossRef

264. PoonRT. Optimal initial treatment for early hepatocellular carcinoma in patients with preserved liver function: transplantation or resection?Ann Surg Oncol2007;14:541. CrossRef

265. PoonRT, FanST, NgIO, et al.Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer2000;89:500. CrossRef

266. PortolaniN, ConiglioA, GhidoniS, et al.Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg2006;243:229. CrossRef

267. HoshidaY, VillanuevaA, KobayashiM, et al.Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med2008;359:1995. CrossRef

268. SamuelM, ChowPK, Chan Shih‐YenE, et al.Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev2009;CD001199.

269. ZhouWP, LaiEC, LiAJ, et al.A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg2009;249:195. CrossRef

270. SingalAK, FreemanDHJr, AnandBS. Meta‐analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther2010;32:851. CrossRef

271. MazzaferroV, RegaliaE, DociR, et al.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med1996;334:693. CrossRef

272. OnacaN, DavisGL, JenningsLW, et al.Improved results of transplantation for hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl2009;15:574. CrossRef

273. DuffyJP, VardanianA, BenjaminE, et al.Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22‐year experience with 467 patients at UCLA. Ann Surg2007;246:502; discussion 509. CrossRef

274. OnacaN, DavisGL, GoldsteinRM, et al.Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl2007;13:391. CrossRef

275. YaoFY, XiaoL, BassNM, et al.Liver transplantation for hepatocellular carcinoma: validation of the UCSF‐expanded criteria based on preoperative imaging. Am J Transplant2007;7:2587. CrossRef

276. YaoFY, FerrellL, BassNM, et al.Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology2001;33:1394. CrossRef

277. MazzaferroV, LlovetJM, MiceliR, et al.Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol2009;10:35. CrossRef

278. VolkML, VijanS, MarreroJA. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant2008;8:839. CrossRef

279. MazzaferroV, BhooriS, SpositoC, et al.Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence‐based analysis of 15 years of experience. Liver Transpl2011;17(Suppl 2):S44. CrossRef

280. PelletierSJ, FuS, ThyagarajanV, et al.An intention‐to‐treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transpl2009;15:859. CrossRef

281. PomfretEA, WashburnK, WaldC, et al.Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl2010;16:262. CrossRef

282. YaoFY, KerlanRKJr, HiroseR, et al.Excellent outcome following down‐staging of hepatocellular carcinoma prior to liver transplantation: an intention‐to‐treat analysis. Hepatology2008;48:819. CrossRef

283. YaoFY. Expanded criteria for hepatocellular carcinoma: down‐staging with a view to liver transplantation – yes. Semin Liver Dis2006;26:239. CrossRef

284. LewandowskiRJ, KulikLM, RiazA, et al.A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant2009;9:1920. CrossRef

285. MaddalaYK, StadheimL, AndrewsJC, et al.Drop‐out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl2004;10:449. CrossRef

286. VitaleA, BoccagniP, BroleseA, et al.Progression of hepatocellular carcinoma before liver transplantation: dropout or liver transplantation?Transplant Proc2009;41:1264. CrossRef

287. ThuluvathPJ, GuidingerMK, FungJJ, et al.Liver transplantation in the United States, 1999‐2008. Am J Transplant2010;10:1003. CrossRef

288. LesurtelM, MullhauptB, PestalozziBC, et al.Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence‐based analysis. Am J Transplant2006;6:2644. CrossRef

289. LlovetJM, MasX, AponteJJ, et al.Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut2002;50:123. CrossRef

290. FisherRA, KulikLM, FreiseCE, et al.Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant2007;7:1601. CrossRef

291. KulikLM, FisherRA, RodrigoDR, et al.Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort. Am J Transplant2012;12:2997. CrossRef

292. KaiharaS, KiuchiT, UedaM, et al.Living‐donor liver transplantation for hepatocellular carcinoma. Transplantation2003;75:S37. CrossRef

293. TodoS, FurukawaH. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg2004;240:451; discussion 459. CrossRef

294. VolkML, MarreroJA, LokAS, et al.Who decides? Living donor liver transplantation for advanced hepatocellular carcinoma. Transplantation2006;82:1136. CrossRef

295. BrownRSJr. Live donors in liver transplantation. Gastroenterology2008;134:1802. CrossRef

296. LencioniR, CrocettiL. Radiofrequency ablation of liver cancer. Tech Vasc Interv Radiol2007;10:38. CrossRef

297. GoldbergSN, GrassiCJ, CardellaJF, et al.Image‐guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol2009;20:S377. CrossRef

298. BrunelloF, VeltriA, CarucciP, et al.Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol2008;43:727. CrossRef

299. LinSM, LinCJ, LinCC, et al.Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology2004;127:1714. CrossRef

300. LinSM, LinCJ, LinCC, et al.Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut2005;54:1151. CrossRef

301. LivraghiT, GoldbergSN, LazzaroniS, et al.Hepatocellular carcinoma: radio‐frequency ablation of medium and large lesions. Radiology2000;214:761. CrossRef

302. ShiinaS, TerataniT, ObiS, et al.A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology2005;129:122. CrossRef

303. ChoYK, KimJK, KimMY, et al.Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology2009;49:453. CrossRef

304. ChoiD, LimHK, RhimH, et al.Percutaneous radiofrequency ablation for early‐stage hepatocellular carcinoma as a first‐line treatment: long‐term results and prognostic factors in a large single‐institution series. Eur Radiol2007;17:684. CrossRef

305. TateishiR, ShiinaS, TerataniT, et al.Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer2005;103:1201. CrossRef

306. N'KontchouG, MahamoudiA, AoutM, et al.Radiofrequency ablation of hepatocellular carcinoma: long‐term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology2009;50:1475. CrossRef

307. ShiinaS, TateishiR, AranoT, et al.Radiofrequency ablation for hepatocellular carcinoma: 10‐year outcome and prognostic factors. Am J Gastroenterol2012;107:569; quiz 578. CrossRef

308. ChenMS, LiJQ, ZhengY, et al.A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg2006;243:321. CrossRef

309. HuangGT, LeePH, TsangYM, et al.Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg2005;242:36. CrossRef

310. LuMD, KuangM, LiangLJ, et al.Surgical resection versus percutaneous thermal ablation for early‐stage hepatocellular carcinoma: a randomized clinical trial]. Zhonghua Yi Xue Za Zhi2006;86:801.

311. ChoYK, RhimH, NohS. Radiofrequency ablation versus surgical resection as primary treatment of hepatocellular carcinoma meeting the Milan criteria: a systematic review. J Gastroenterol Hepatol2011;26:1354.

312. MolinariM, HeltonS. Hepatic resection versus radiofrequency ablation for hepatocellular carcinoma in cirrhotic individuals not candidates for liver transplantation: a Markov model decision analysis. Am J Surg2009;198:396. CrossRef

313. IannittiDA, DupuyDE, Mayo‐SmithWW, et al.Hepatic radiofrequency ablation. Arch Surg2002;137:422; discussion 427. CrossRef

314. PompiliM, MiranteVG, RondinaraG, et al.Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl2005;11:1117. CrossRef

315. MulierS, NiY, JamartJ, et al.Local recurrence after hepatic radiofrequency coagulation: multivariate meta‐analysis and review of contributing factors. Ann Surg2005;242:158. CrossRef

316. VeltriA, MorettoP, DoriguzziA, et al.Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non‐early hepatocellular carcinoma (HCC). Eur Radiol2006;16:661. CrossRef

317. KimSW, RhimH, ParkM, et al.Percutaneous radiofrequency ablation of hepatocellular carcinomas adjacent to the gallbladder with internally cooled electrodes: assessment of safety and therapeutic efficacy. Korean J Radiol2009;10:366. CrossRef

318. KomorizonoY, OketaniM, SakoK, et al.Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer2003;97:1253. CrossRef

319. LlovetJM, VilanaR, BruC, et al.Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology2001;33:1124. CrossRef

320. LuDS, YuNC, RamanSS, et al.Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology2005;234:954. CrossRef

321. LivraghiT, SolbiatiL, MeloniMF, et al.Treatment of focal liver tumors with percutaneous radio‐frequency ablation: complications encountered in a multicenter study. Radiology2003;226:441. CrossRef

322. GiorgioA, TarantinoL, de StefanoG, et al.Complications after percutaneous saline‐enhanced radiofrequency ablation of liver tumors: 3‐year experience with 336 patients at a single center. Am J Roentgenol2005;184:207. CrossRef

323. SekiT, WakabayashiM, NakagawaT, et al.Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer1994;74:817. CrossRef

324. SatoM, WatanabeY, UedaS, et al.Microwave coagulation therapy for hepatocellular carcinoma. Gastroenterology1996;110:1507. CrossRef

325. BoutrosC, SomasundarP, GarreanS, et al.Microwave coagulation therapy for hepatic tumors: review of the literature and critical analysis. Surg Oncol2010;19:e22. CrossRef

326. ShibataT, IimuroY, YamamotoY, et al.Small hepatocellular carcinoma: comparison of radio‐frequency ablation and percutaneous microwave coagulation therapy. Radiology2002;223:331. CrossRef

327. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med1995;332:1256. CrossRef

328. BruixJ, LlovetJM. Two decades of advances in hepatocellular carcinoma research. Semin Liver Dis2010;30:1. CrossRef

329. LlovetJM, RealMI, MontanaX, et al.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet2002;359:1734. CrossRef

330. ChungGE, LeeJH, KimHY, et al.Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology2011;258:627. CrossRef

331. YamadaR, SatoM, KawabataM, et al.Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology1983;148:397. CrossRef

332. PomoniM, MalagariK, MoschourisH, et al.Post embolization syndrome in doxorubicin eluting chemoembolization with DC bead. Hepatogastroenterology2012;59:820.

333. VarelaM, RealMI, BurrelM, et al.Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol2007;46:474. CrossRef

334. LammerJ, MalagariK, VoglT, et al.Prospective randomized study of doxorubicin‐eluting‐bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol2010;33:41. CrossRef

335. MalagariK, PomoniM, KelekisA, et al.Prospective randomized comparison of chemoembolization with doxorubicin‐eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol2010;33:541. CrossRef

336. BurrelM, ReigM, FornerA, et al.Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol2012;56:1330. CrossRef

337. GeschwindJF, SalemR, CarrBI, et al.Yttrium‐90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology2004;127:S194. CrossRef

338. IbrahimSM, LewandowskiRJ, SatoKT, et al.Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol2008;14:1664. CrossRef

339. SalemR, LewandowskiRJ, AtassiB, et al.Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol2005;16:1627. CrossRef

340. SalemR, LewandowskiRJ, KulikL, et al.Radioembolization results in longer time‐to‐progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology2011;140:497. CrossRef

341. KulikLM, CarrBI, MulcahyMF, et al.Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology2008;47:71. CrossRef

342. SalemR, LewandowskiRJ, MulcahyMF, et al.Radioembolization for hepatocellular carcinoma using yttrium‐90 microspheres: a comprehensive Report of long‐term outcomes. Gastroenterology2010;138:52. CrossRef

343. ZhuAX. Systemic treatment of hepatocellular carcinoma: dawn of a new era?Ann Surg Oncol2010;17:1247. CrossRef

344. LlovetJM, RicciS, MazzaferroV, et al.Sorafenib in advanced hepatocellular carcinoma. N Engl J Med2008;359:378. CrossRef

345. ChengAL, KangYK, ChenZ, et al.Efficacy and safety of sorafenib in patients in the Asia‐Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double‐blind, placebo‐controlled trial. Lancet Oncol2009;10:25. CrossRef

346. LencioniR, KudoM, YeSL, et al.First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non‐interventional study. 2010;64:1043

347. WornsMA, WeinmannA, PfingstK, et al.Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol2009;43:489. CrossRef

348. PrintzC. Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM). Cancer2009;115:4646. CrossRef

349. HoffmannK, GlimmH, RadeleffB, et al.Prospective, randomized, double‐blind, multi‐center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation – HeiLivCa [ISRCTN24081794]. BMC Cancer2008;8:349. CrossRef

350. StauferK, FischerL, SeegersB, et al.High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Transpl Int2012;25:1158. CrossRef

351. ChengA, KangYK, LinD, et al.Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol2011;29S:Abstract 4000.

352. FinnRS, KangYK, MulcahyM, et al.Phase II, open‐label study of brivanib as second‐line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res2012;18:2090. CrossRef

353. ParkJW, FinnRS, KimJS, et al.Phase II, open‐label study of brivanib as first‐line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res2011;17:1973. CrossRef

354. AngC, O'ReillyEM, Abou‐AlfaGK. Targeted agents and systemic therapy in hepatocellular carcinoma. Recent Results Cancer Res2013;190:225. CrossRef

355. KasebAO, Garrett‐MayerE, MorrisJS, et al.Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology2012;82:67. CrossRef

356. O'NeilBH, GoffLW, KauhJS, et al.Phase II study of the mitogen‐activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol2011;29:2350. CrossRef

357. PhilipPA, MahoneyMR, HolenKD, et al.Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer. Cancer2012;118:2424. CrossRef

358. SiegelAB, CohenEI, OceanA, et al.Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol2008;26:2992. CrossRef

359. ThomasMB, MorrisJS, ChadhaR, et al.Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol2009;27:843. CrossRef

360. ZhuQ, LiJ, YanJJ, et al.Predictors and clinical outcomes for spontaneous rupture of hepatocellular carcinoma. World J Gastroenterol2012;18:7302. CrossRef

361. MiyoshiA, KitaharaK, KohyaN, et al.Miyazahi K. Outcomes of patients with spontaneous rupture of hepatocellular carcinoma. Hepatogastroenterology2011;58:99.

362. TarantinoL, SordelliI, CaliseF, et al.Prognosis of patients with spontaneous rupture of hepatocellular carcinoma in cirrhosis. Updates Surg2011;63:25. CrossRef

363. WangB, LuY, ZhangXF, et al.Management of spontaneous rupture of hepatocellular carcinoma. ANZ J Surg2008;78:501. CrossRef

364. LiuCL, FanST, LoCM, et al.Management of spontaneous rupture of hepatocellular carcinoma: single‐center experience. J Clin Oncol2001;19:3725.

365. LeungKL, LauWY, LaiPB, et al.Spontaneous rupture of hepatocellular carcinoma: conservative management and selective intervention. Arch Surg1999;134:1103. CrossRef

366. KewMC. Prevention of hepatocellular carcinoma. HPB (Oxford)2005;7:16. CrossRef

367. ChangMH, ChenCJ, LaiMS, et al.Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med1997;336:1855. CrossRef

368. ChangMH, YouSL, ChenCJ, et al.Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20‐year follow‐up study. J Natl Cancer Inst2009;101:1348. CrossRef

369. GoldsteinST, ZhouF, HadlerSC, et al.A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol2005;34:1329. CrossRef

370. LinSM, SheenIS, ChienRN, et al.Long‐term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology1999;29:971. CrossRef

371. LiawYF, SungJJ, ChowWC, et al.Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med2004;351:1521. CrossRef

372. LoCM, LiuCL, ChanSC, et al.A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg2007;245:831. CrossRef

373. SunHC, TangZY, WangL, et al.Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV‐related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol2006;132:458. CrossRef

374. WuCY, ChenYJ, HoHJ, et al.Association between nucleoside analogues and risk of hepatitis B virus‐related hepatocellular carcinoma recurrence following liver resection. JAMA2012;308:1906. CrossRef

375. AlterMJ. Healthcare should not be a vehicle for transmission of hepatitis C virus. J Hepatol2008;48:2. CrossRef

376. NishiguchiS, KurokiT, NakataniS, et al.Randomised trial of effects of interferon‐alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet1995;346:1051. CrossRef

377. ShiffmanML, Di BisceglieAM, LindsayKL, et al.Peginterferon alfa‐2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology2004;126:1015; discussion 1947. CrossRef

378. BruixJ, PoynardT, ColomboM, et al.Maintenance therapy with peginterferon alfa‐2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology2011;140:1990. CrossRef

379. MazzaferroV, RomitoR, SchiavoM, et al.Prevention of hepatocellular carcinoma recurrence with alpha‐interferon after liver resection in HCV cirrhosis. Hepatology2006;44:1543. CrossRef

380. KudoM, SakaguchiY, ChungH, et al.Long‐term interferon maintenance therapy improves survival in patients with HCV‐related hepatocellular carcinoma after curative radiofrequency ablation. A matched case‐control study. Oncology2007;72:132. CrossRef

381. JeongSC, AikataH, KatamuraY, et al.Effects of a 24‐week course of interferon‐alpha therapy after curative treatment of hepatitis C virus‐associated hepatocellular carcinoma. World J Gastroenterol2007;13:5343. CrossRef

382. DemierreMF, HigginsPD, GruberSB, et al.Statins and cancer prevention. Nat Rev Cancer2005;5:930. CrossRef

383. SinghS, SinghPP, SinghAG, et al.Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta‐analysis. Gastroenterology2013;144:323. CrossRef

384. RuhlCE, EverhartJE. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology2005;128:24. CrossRef

385. CavinC, HolzhauserD, ConstableA, et al.The coffee‐specific diterpenes cafestol and kahweol protect against aflatoxin B1‐induced genotoxicity through a dual mechanism. Carcinogenesis1998;19:1369. CrossRef

386. CorraoG, ZambonA, BagnardiV, et al.Coffee, caffeine, and the risk of liver cirrhosis. Ann Epidemiol2001;11:458. CrossRef

387. GallusS, TavaniA, NegriE, et al.Does coffee protect against liver cirrhosis?Ann Epidemiol2002;12:202. CrossRef

388. BraviF, BosettiC, TavaniA, et al.Coffee drinking and hepatocellular carcinoma: an update. Hepatology2009;50:1317. CrossRef

389. BraviF, BosettiC, TavaniA, et al.Coffee drinking and hepatocellular carcinoma risk: a meta‐analysis. Hepatology2007;46:430. CrossRef